Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) announced the completion of the Company’s Annual General Meeting held in Vancouver on June 26, 2003. The shareholders have re-elected the following five members of the Board of Directors.
Dr. Alexander Wick, President and Chief Executive Officer
Dr. Longbin Liu, M.D., Chairman of the Board of Directors
Dr. Ken Z. Cai, Ph.D., Director
Dr. Y.K. Sun, M.B., B.S. (HK), Director
Mr. Philip Yuen, Director
Prior to the Annual General Meeting, Mr. Greg Hall, a member of the Board of Directors since 1998, withdrew his nomination as a Director of the Company due to personal reasons. “On behalf of Dragon’s Board of Directors and the management team, I wish to express our sincere appreciation to Mr. Hall for his contribution to the Company. As a director of the Company, Mr. Hall had shared many responsibilities that led to prompt and sound decisions by the Board.” said Dr. Alexander Wick, President and Chief Executive Officer of Dragon.
The Company also announced that shareholders of the Company have ratified the re-appointment of Moore Stephens Ellis Foster Ltd., Chartered Accountants, to audit Dragon’s financial statements for the year ending December 31, 2003.
About Dragon Pharmaceutical Dragon Pharmaceutical Inc. is an international biopharmaceutical company headquartered in Vancouver, Canada, with cGMP production and research and development facilities in Nanjing, China. The Company develops and commercializes human proteins for therapeutic use. Based on its proven protein expression technology, Dragon believes that it has become a competitive producer of Erythropoietin (EPO), a breakthrough drug that has revolutionized the treatment of anemia. Dragon’s EPO is currently approved to treat anemia due to renal failure and surgery in China, India, Brazil, Egypt and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Asia, Latin America, the Middle East and Africa.
Legal Dragon Pharma
243 total views, 1 today